GlassScriptPhysician profile
Olena Andikyan
NPI 1205547999
$4,502.34
in general payments reported to CMS, 2019-2025
29 companies · $2,606 in 2025
The $2,606 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,099 · 2024: $797 · 2025: $2,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,402 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $843.79 | 2023-2025 | |
| Janssen Biotech, INC. | $689.03 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $467.50 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $372.53 | 2023-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $217.23 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $212.33 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $171.88 | 2023-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $171.81 | 2025 | Nemluvio |
| Botanix Sb INC | $166.22 | 2025 | Sofdra |
| Ucb, INC. | $140.51 | 2025 | Bimzelx |
| Organon LLC | $136.83 | 2025 | Vtama |
| Pfizer INC. | $124.68 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.20 | 2023-2024 | Jublia, Cabtreo |
| Novartis Pharmaceuticals Corporation | $117.05 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $81.66 | 2023-2024 | Ycanth |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $74.56 | 2023-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $73.79 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $43.07 | 2024 | Vtama |
| Endo USA, INC. | $42.68 | 2024 | Xiaflex |
| Endo Pharmaceuticals INC. | $37.19 | 2023-2024 | Xiaflex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.02 | 2025 | Spevigo |
| Smith+Nephew, INC. | $27.21 | 2024 | Grafix, Stravix |
| Almirall LLC | $26.59 | 2025 | Seysara |
| Amgen INC. | $21.41 | 2025 | Otezla |
| Strata Skin Sciences, INC. | $19.17 | 2025 | Xtrac |
| Glaxosmithkline, LLC. | $18.32 | 2025 | Nucala |
| Journey Medical Corporation | $17.92 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $17.60 | 2023 | Valchlor |
| Solventum Corporation | $13.56 | 2024 | Activ.A.C., Promogran Prisma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olena Andikyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.